Aileron Therapeutics Inc.

12/10/2024 | Press release | Distributed by Public on 12/10/2024 19:35

Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low Dose LTI 03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.